ArticleDrug design, development and therapy2026

Clinical Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitors for the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer Based on the 2nd Edition of China's Drug Evaluation and Selection Guideline.

Zhijun Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.